Literature DB >> 32275903

Mammalian Target of Rapamycin Complex 2 Signaling Is Required for Liver Regeneration in a Cholestatic Liver Injury Murine Model.

Yi Zhou1, Meng Xu2, Pin Liu3, Binyong Liang4, Manning Qian5, Haichuan Wang6, Xinhua Song7, Pranavanand Nyshadham8, Li Che7, Diego F Calvisi9, Feng Li8, Shumei Lin10, Xin Chen11.   

Abstract

Cholestatic liver injury may lead to a series of hepatobiliary syndromes, which can progress to cirrhosis and impaired liver regeneration, eventually resulting in liver-related death. Mammalian target of rapamycin complex 2 (mTORC2) is a major regulator of liver metabolism and tumor development. However, the role of mTORC2 signaling in cholestatic liver injury has not been characterized to date. In this study, we generated liver-specific Rictor knockout mice to block the mTORC2 signaling pathway. Mice were treated with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) to induce cholestatic liver injury. DDC feeding induced cholestatic liver injury and ductular reaction as well as activation of the mTORC2/Akt signaling pathway in wild-type mice. Loss of mTORC2 led to significantly decreased oval cell expansion after DDC feeding. Mechanistically, this phenotype was independent of mTORC1/fatty acid synthase cascade (Fasn) or yes-associated protein (Yap) signaling. Notch pathway was instead strongly inhibited during DDC-induced cholestatic liver injury in liver-specific Rictor knockout mice. Furthermore, mTORC2 deficiency in adult hepatocytes did not inhibit ductular reaction in this cholestatic live injury mouse model. Our results indicated that mTORC2 signaling effectively regulates liver regeneration by inducing oval cell proliferation. Liver progenitor cells or bile duct cells, rather than mature hepatocytes, would be the major source of ductular reaction in DDC-induced cholestatic liver injury.
Copyright © 2020 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32275903      PMCID: PMC7341974          DOI: 10.1016/j.ajpath.2020.03.010

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 2.  Determining the fate of hepatic cells by lineage tracing: facts and pitfalls.

Authors:  Frédéric P Lemaigre
Journal:  Hepatology       Date:  2015-04-15       Impact factor: 17.425

3.  Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling.

Authors:  Bart Spee; Guido Carpino; Baukje A Schotanus; Azeam Katoonizadeh; Sara Vander Borght; Eugenio Gaudio; Tania Roskams
Journal:  Gut       Date:  2009-11-01       Impact factor: 23.059

4.  Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.

Authors:  Chunmei Wang; Li Che; Junjie Hu; Shanshan Zhang; Lijie Jiang; Gavinella Latte; Maria I Demartis; Junyan Tao; Bing Gui; Maria G Pilo; Silvia Ribback; Frank Dombrowski; Matthias Evert; Diego F Calvisi; Xin Chen
Journal:  Liver Int       Date:  2016-01-30       Impact factor: 5.828

5.  Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2.

Authors:  Vivian A Galicia; Lina He; Hien Dang; Gary Kanel; Christopher Vendryes; Barbara A French; Ni Zeng; Jennifer-Ann Bayan; Wei Ding; Kasper S Wang; Samuel French; Morris J Birnbaum; C Bart Rountree; Bangyan L Stiles
Journal:  Gastroenterology       Date:  2010-09-15       Impact factor: 22.682

Review 6.  Growing roles for the mTOR pathway.

Authors:  Dos D Sarbassov; Siraj M Ali; David M Sabatini
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

7.  Akt2 is required for hepatic lipid accumulation in models of insulin resistance.

Authors:  Karla F Leavens; Rachael M Easton; Gerald I Shulman; Stephen F Previs; Morris J Birnbaum
Journal:  Cell Metab       Date:  2009-11       Impact factor: 27.287

Review 8.  The role of the mTOR pathway during liver regeneration and tumorigenesis.

Authors:  Ganna Panasyuk; Cecilia Patitucci; Catherine Espeillac; Mario Pende
Journal:  Ann Endocrinol (Paris)       Date:  2013-04-06       Impact factor: 2.478

9.  mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis.

Authors:  R W Hallowell; S L Collins; J M Craig; Y Zhang; M Oh; P B Illei; Y Chan-Li; C L Vigeland; W Mitzner; A L Scott; J D Powell; M R Horton
Journal:  Nat Commun       Date:  2017-01-27       Impact factor: 14.919

10.  Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.

Authors:  Zhong Xu; Junjie Hu; Hui Cao; Maria G Pilo; Antonio Cigliano; Zixuan Shao; Meng Xu; Silvia Ribback; Frank Dombrowski; Diego F Calvisi; Xin Chen
Journal:  Exp Mol Med       Date:  2018-01-05       Impact factor: 8.718

View more
  3 in total

Review 1.  Liver regeneration biology: Implications for liver tumour therapies.

Authors:  Christopher Hadjittofi; Michael Feretis; Jack Martin; Simon Harper; Emmanuel Huguet
Journal:  World J Clin Oncol       Date:  2021-12-24

2.  Metabonomics study on the hepatoprotective effect mechanism of polysaccharides from different processed products of Angelica sinensis on layer chickens based on UPLC-Q/TOF-MS/MS, multivariate statistical analysis and conjoint analysis.

Authors:  Fan-Lin Wu; Yong-Hao Hu; Peng Ji; Chen-Chen Li; Jian He
Journal:  Biomed Chromatogr       Date:  2022-04-26       Impact factor: 1.911

3.  YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.

Authors:  Xinjun Lu; Baogang Peng; Ge Chen; Mario G Pes; Silvia Ribback; Cindy Ament; Hongwei Xu; Rajesh Pal; Pedro M Rodrigues; Jesus M Banales; Matthias Evert; Diego F Calvisi; Xin Chen; Biao Fan; Jingxiao Wang
Journal:  Am J Pathol       Date:  2021-06-12       Impact factor: 5.770

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.